Cargando…

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study

AIM: To assess the efficacy of pegaptanib as maintenance therapy in neovascular age-related macular degeneration (NV-AMD) patients after induction therapy. METHODS: A phase IV, prospective, open-label, uncontrolled exploratory study including subjects with subfoveal NV-AMD who had had one to three i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friberg, Thomas R, Tolentino, Michael
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991041/ https://www.ncbi.nlm.nih.gov/pubmed/20472746 http://dx.doi.org/10.1136/bjo.2009.174946

Ejemplares similares

Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008)

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sivaprasad, Sobha, et al.
Publicado: (2008)

Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
por: Feucht, Nikolaus, et al.
Publicado: (2008)

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
por: Querques, G., et al.
Publicado: (2009)

Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006)

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008)

Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
por: Shiragami, Chieko, et al.
Publicado: (2014)

A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus
por: Dombi, Theresa, et al.
Publicado: (2012)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Nishimura, Yoshihiro, et al.
Publicado: (2012)

Clinical experience with pegaptanib sodium
por: Rosina, Chiara, et al.
Publicado: (2008)

Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema
por: Basile, Anthony S, et al.
Publicado: (2015)

Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone
por: Yip, P P, et al.
Publicado: (2009)

Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting
por: Kataja, Maria, et al.
Publicado: (2018)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration
por: Grixti, Andre, et al.
Publicado: (2014)

Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study
por: Weber, Pamela A, et al.
Publicado: (2010)

Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
por: Frenkel, Ronald E P, et al.
Publicado: (2016)

Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Pegaptanib sodium for ocular vascular disease
por: Shukla, Dhananjay, et al.
Publicado: (2007)

Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy
por: Keane, Pearse A., et al.
Publicado: (2011)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response
por: Hatz, Katja, et al.
Publicado: (2014)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
por: Bandello, Francesco, et al.
Publicado: (2020)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

Measuring dynamic levels of self-perceived anxiety and concern during simulated mobility tasks in people with non-neovascular age-related macular degeneration
por: Taylor, Deanna J, et al.
Publicado: (2020)

Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration
por: Mazaraki, Kyriaki, et al.
Publicado: (2015)

Treatment of neovascular age-related macular degeneration: Current therapies
por: Augustin, Albert J, et al.
Publicado: (2009)

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
por: Samanta, Anindya, et al.
Publicado: (2020)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire, Christine A, et al.
Publicado: (2015)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
por: Menke, Marcel N, et al.
Publicado: (2014)

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
por: Gale, Richard P, et al.
Publicado: (2020)

Age-related macular degeneration: choroidal ischaemia?
por: Coleman, D Jackson, et al.
Publicado: (2013)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration
por: Nita, Małgorzata, et al.
Publicado: (2014)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_95427n3h27d82abl0oieb92vnd